CS-1103

Clear Scientific, Inc. · Phase 2 active Small molecule

At a glance

Generic name	CS-1103
Sponsor	Clear Scientific, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade (PHASE2)
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine (PHASE2)
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CS-1103 CI brief — competitive landscape report
CS-1103 updates RSS · CI watch RSS
Clear Scientific, Inc. portfolio CI